Cipher Pharmaceuticals Inc (TO:CPH) — Market Cap & Net Worth
Market Cap & Net Worth: Cipher Pharmaceuticals Inc (CPH)
Cipher Pharmaceuticals Inc (TO:CPH) has a market capitalization of $267.68 Million (CA$370.04 Million) as of September 17, 2026. Listed on the TO stock exchange, this Canada-based company holds position #15433 globally and #466 in its home market, demonstrating a 1.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cipher Pharmaceuticals Inc's stock price CA$14.56 by its total outstanding shares 25415072 (25.42 Million). Also see Cipher Pharmaceuticals Inc assets under control for a full breakdown of the balance sheet.
Cipher Pharmaceuticals Inc Market Cap History: 2015 to 2026
Cipher Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $119.32 Million to $267.68 Million (9.87% CAGR). Also see cash flow conversion of Cipher Pharmaceuticals Inc for how efficiently the company converts equity into cash flow.
Cipher Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cipher Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Cipher Pharmaceuticals Inc (CPH) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
5.39x
Cipher Pharmaceuticals Inc's market cap is 5.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.96x
Cipher Pharmaceuticals Inc's market cap is 9.96 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $90.09 Million | $40.74 Million | -$39.15 Million | 2.21x | N/A |
| 2017 | $90.09 Million | $40.32 Million | $4.40 Million | 2.23x | 20.46x |
| 2018 | $31.44 Million | $22.75 Million | $543.00K | 1.38x | 57.90x |
| 2019 | $27.58 Million | $22.45 Million | $3.24 Million | 1.23x | 8.51x |
| 2020 | $17.10 Million | $21.61 Million | $4.55 Million | 0.79x | 3.76x |
| 2021 | $32.54 Million | $21.94 Million | $7.76 Million | 1.48x | 4.19x |
| 2022 | $70.60 Million | $20.68 Million | $26.64 Million | 3.41x | 2.65x |
| 2023 | $101.85 Million | $21.16 Million | $20.38 Million | 4.81x | 5.00x |
| 2024 | $263.27 Million | $33.36 Million | $11.54 Million | 7.89x | 22.80x |
| 2025 | $276.88 Million | $51.33 Million | $27.81 Million | 5.39x | 9.96x |
Competitor Companies of CPH by Market Capitalization
Companies near Cipher Pharmaceuticals Inc in the global market cap rankings as of September 17, 2026. Review tangible net worth ratio of Cipher Pharmaceuticals Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cipher Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Cipher Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Cipher Pharmaceuticals Inc's market cap moved from $119.32 Million to $ 267.68 Million, with a yearly change of 9.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$267.68 Million | -3.32% |
| 2025 | CA$276.88 Million | +5.17% |
| 2024 | CA$263.27 Million | +158.48% |
| 2023 | CA$101.85 Million | +44.27% |
| 2022 | CA$70.60 Million | +116.95% |
| 2021 | CA$32.54 Million | +90.32% |
| 2020 | CA$17.10 Million | -38.00% |
| 2019 | CA$27.58 Million | -12.28% |
| 2018 | CA$31.44 Million | -65.10% |
| 2017 | CA$90.09 Million | 0.00% |
| 2016 | CA$90.09 Million | -24.50% |
| 2015 | CA$119.32 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Cipher Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $267.68 Million USD |
| MoneyControl | $267.68 Million USD |
| MarketWatch | $267.68 Million USD |
| marketcap.company | $267.68 Million USD |
| Reuters | $267.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead… Read more